IN2014MN01879A - - Google Patents
Info
- Publication number
- IN2014MN01879A IN2014MN01879A IN1879MUN2014A IN2014MN01879A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A IN 1879MUN2014 A IN1879MUN2014 A IN 1879MUN2014A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- antibody chains
- derivatives
- chimaeric
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/433,084 US9445581B2 (en) | 2012-03-28 | 2012-03-28 | Animal models and therapeutic molecules |
US13/434,361 US9253965B2 (en) | 2012-03-28 | 2012-03-29 | Animal models and therapeutic molecules |
PCT/GB2013/050682 WO2013144566A2 (en) | 2012-03-28 | 2013-03-18 | Animal models and therapeutic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01879A true IN2014MN01879A (ar) | 2015-07-03 |
Family
ID=47913490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1879MUN2014 IN2014MN01879A (ar) | 2012-03-28 | 2013-03-18 |
Country Status (12)
Country | Link |
---|---|
US (7) | US9253965B2 (ar) |
EP (3) | EP2785845A2 (ar) |
JP (4) | JP6336435B2 (ar) |
CN (1) | CN104334732B (ar) |
AU (1) | AU2013239501B2 (ar) |
CA (1) | CA2867530A1 (ar) |
DK (1) | DK2831244T3 (ar) |
HK (1) | HK1200872A1 (ar) |
IN (1) | IN2014MN01879A (ar) |
NZ (1) | NZ629202A (ar) |
SG (1) | SG11201405058WA (ar) |
WO (2) | WO2013061098A2 (ar) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102719444B (zh) | 2006-09-01 | 2016-12-14 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
LT3241435T (lt) | 2009-07-08 | 2021-10-25 | Kymab Limited | Gyvūnų modeliai ir terapinės molekulės |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
CA2806233C (en) | 2010-07-26 | 2021-12-07 | Trianni, Inc. | Transgenic animals and methods of use |
EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
IN2013CN07629A (ar) | 2011-02-25 | 2015-08-07 | Regeneron Pharma | |
RU2664232C2 (ru) | 2011-08-05 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной универсальной легкой цепью |
EP2758535B1 (en) | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
PL2627773T3 (pl) | 2011-10-17 | 2017-11-30 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
EP3527070A1 (en) | 2011-12-20 | 2019-08-21 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10238093B2 (en) | 2012-06-12 | 2019-03-26 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
ES2859373T3 (es) * | 2013-10-01 | 2021-10-01 | Kymab Ltd | Modelos animales y moléculas terapéuticas |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
KR20230158661A (ko) | 2014-03-21 | 2023-11-21 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
SI3126383T1 (sl) | 2014-04-03 | 2019-05-31 | Igm Biosciences, Inc. | Modificirana veriga J |
AU2016226060B2 (en) | 2015-03-04 | 2020-04-23 | Igm Biosciences, Inc. | CD20 binding molecules and uses thereof |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
AU2016329197B2 (en) | 2015-09-30 | 2021-01-21 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
EP3384030A4 (en) | 2015-12-03 | 2019-07-03 | Trianni, Inc. | IMPROVED IMMUNOGLULINIVITY |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CN117736325A (zh) | 2016-08-09 | 2024-03-22 | 科马布有限公司 | 分离抗体及其应用 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
WO2018144097A1 (en) * | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
SI3766343T1 (sl) * | 2016-11-04 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nehumane živali z modificiranim lokusom lahke verige lambda imunoglobulina |
MA46959A (fr) | 2016-12-02 | 2019-10-09 | Juno Therapeutics Inc | Cellules b modifiées et compositions et méthodes associées |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
JP6947825B2 (ja) * | 2017-07-21 | 2021-10-13 | 株式会社 アイロムグループ | 標的配列を改変するためのポリヌクレオチドおよびその使用 |
WO2019037099A1 (en) * | 2017-08-25 | 2019-02-28 | Wenning Qin | LARGE SCALE MODIFICATION OF GENOME EUCARYOTE |
DK3720279T3 (da) * | 2017-12-05 | 2022-10-24 | Regeneron Pharma | Mus med et modificeret immunoglobulin-Lambda-letkæde og anvendelser deraf |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
CN108486126A (zh) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在人源化抗体中的应用 |
GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
CN117099741A (zh) | 2019-02-18 | 2023-11-24 | 百奥赛图(北京)医药科技股份有限公司 | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 |
KR20210150506A (ko) | 2019-04-09 | 2021-12-10 | 압큐로, 인크. | 킬러 세포 렉틴 유사-수용체 서브패밀리 G 구성원 1(KLRGl) 고갈 항체 |
AU2020299569A1 (en) * | 2019-07-01 | 2022-01-20 | Trianni, Inc. | Transgenic mammals and methods of use |
MX2022006495A (es) | 2019-11-29 | 2022-09-07 | Kymab Ltd | Tratamiento para la sobrecarga fisiologica de hierro. |
CN115988960A (zh) | 2020-06-25 | 2023-04-18 | 株式会社湖美宝 | 杂合转基因动物 |
WO2022026775A1 (en) * | 2020-07-30 | 2022-02-03 | Prellis Biologics, Inc | Compositions and methods for targeting coronavirus |
TW202229328A (zh) | 2020-09-11 | 2022-08-01 | 美商再生元醫藥公司 | 抗原特異性抗體之鑑定及產生 |
US20240065239A1 (en) | 2020-12-16 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
AU2022320627A1 (en) | 2021-07-26 | 2024-02-08 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US4720449A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
ES2108048T3 (es) * | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Cd40リガンド遺伝子の突然変異の検出および治療 |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
DE4331162A1 (de) | 1993-09-14 | 1995-03-16 | Bayer Ag | Verfahren zur Herstellung von Cyaninfarbstoffen |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
CA2250830A1 (en) | 1996-06-26 | 1997-12-31 | Binhai Zheng | Chromosomal rearrangement by insertion of two recombination substrates |
WO1997049805A2 (en) | 1996-06-27 | 1997-12-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
ATE302271T1 (de) | 1997-11-18 | 2005-09-15 | Pioneer Hi Bred Int | Zusammensetzungen und verfahren für die genetische modifizierung von pflanzen |
EP1291420B1 (en) | 1997-12-05 | 2009-11-25 | Europäisches Laboratorium Für Molekularbiologie (Embl) | Novel DNA cloning method relying on the E.coli RECE/RECT recombination system |
EP0939120A1 (en) | 1998-02-27 | 1999-09-01 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US6355412B1 (en) | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2307503A1 (en) | 2000-05-02 | 2001-11-02 | Carlos F. Barbas Iii | Peptides for use as a vaccine or treatment for hiv infection |
JP2004504055A (ja) | 2000-07-21 | 2004-02-12 | アメリカ合衆国 | 真核生物ゲノムにおけるdnaの置換、転座およびスタッキングの方法 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1343880B1 (en) | 2000-11-17 | 2009-05-27 | Kyowa Hakko Kirin Co., Ltd. | Expression of xenogenous (human) immunoglobulins in cloned, transgenic bovine |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
CZ301712B6 (cs) | 2001-01-05 | 2010-06-02 | Pfizer Inc. | Protilátka k receptoru IGF-I a farmaceutický prípravek obsahující tuto protilátku |
FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
DK2319301T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
US20050095712A1 (en) | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US20040128703A1 (en) | 2002-09-09 | 2004-07-01 | Hiroaki Shizuya | Methods and compositions for the generation of humanized mice |
US7700356B2 (en) | 2002-11-08 | 2010-04-20 | The United States Of America As Represented By The Secretary Of Agriculture | System for gene targeting and producing stable genomic transgene insertions |
DE10251918A1 (de) | 2002-11-08 | 2004-05-19 | Horn, Carsten, Dipl.-Biochem. Dr. | Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005001087A2 (en) | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
JP2005042792A (ja) | 2003-07-28 | 2005-02-17 | Nsk Ltd | ローラクラッチ及びローラクラッチ内蔵型プーリ装置 |
US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
US7604994B2 (en) | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
CA2445602C (en) | 2003-10-20 | 2014-01-14 | Campusgen Gmbh | Nucleotide sequence for creatinine deiminase and method of use |
SI2383295T1 (sl) | 2003-12-10 | 2015-07-31 | E.R. Squibb & Sons, L.L.C. | Protitelesa IP-10 in njihova uporaba |
US20050260679A1 (en) | 2004-03-19 | 2005-11-24 | Sirid-Aimee Kellerman | Reducing the risk of human anti-human antibodies through V gene manipulation |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
PL1776383T3 (pl) | 2004-07-22 | 2015-02-27 | Univ Erasmus Med Ct Rotterdam | Cząsteczki wiążące |
FR2875239B1 (fr) | 2004-09-10 | 2007-07-20 | Inst Necker Ass Loi De 1901 | Procede pour l'acceleration des mutations somatiques et son application en proteomique |
WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
DK2767161T3 (en) | 2004-10-19 | 2018-05-07 | Regeneron Pharma | Method of generating an animal homozygous for genetic modification |
WO2006055704A2 (en) | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
MX2007007484A (es) | 2004-12-21 | 2007-07-20 | Astrazeneca Ab | Anticuerpos dirigidos a angiopoyetina 2 y usos de los mismos. |
AU2005331864A1 (en) | 2005-05-14 | 2006-11-23 | Fudan University | Piggybac as a tool for genetic manipulation and analysis in vertebrates |
EP1780272A1 (en) | 2005-10-27 | 2007-05-02 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method for enhancing somatic hypermutation, gene conversion and class switch recombination |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
RU2435784C2 (ru) | 2006-01-25 | 2011-12-10 | Эрасмус Юниверсити Медикал Сентр Роттердам | Получение антител из одних тяжелых цепей в трансгенных животных |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
AU2007235496B2 (en) * | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
US7709257B2 (en) | 2006-06-27 | 2010-05-04 | Vax Design Corp. | Models for vaccine assessment |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
US8084024B2 (en) | 2006-08-22 | 2011-12-27 | G2 Inflammation Pty Ltd | Method for producing antibodies |
EP2069403B1 (en) | 2006-10-02 | 2014-05-07 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
WO2008070367A2 (en) | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
KR101540822B1 (ko) | 2007-03-27 | 2015-07-30 | 씨 레인 바이오테크놀로지스, 엘엘씨 | 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리 |
GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
HUE037302T2 (hu) | 2007-06-01 | 2018-08-28 | Open Monoclonal Tech Inc | Készítmények és eljárások endogén immunglobulin gének gátlására és transzgenikus humán idiotipikus antianyagok elõállítása |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
CN101809037B (zh) | 2007-07-31 | 2014-01-15 | 瑞泽恩制药公司 | 人cd20的人抗体及其使用方法 |
EP2572729A3 (en) | 2007-08-10 | 2013-06-05 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
EP3255144A1 (en) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin |
JP2009122383A (ja) * | 2007-11-14 | 2009-06-04 | Canon Inc | 揺動体装置の製造方法、該製造方法により製造された揺動体装置によって構成される光偏向器及び光学機器 |
WO2009076464A2 (en) | 2007-12-10 | 2009-06-18 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
CN101978000A (zh) | 2008-01-25 | 2011-02-16 | 卡伯特公司 | 制备改性有色颜料的方法 |
KR101409375B1 (ko) | 2008-01-31 | 2014-06-18 | 삼성전자주식회사 | 반도체 메모리장치의 블록 디코딩 회로 |
JP2011515098A (ja) | 2008-03-26 | 2011-05-19 | アイティーアイ・スコットランド・リミテッド | 胚性幹細胞へのdnaの効率的な挿入 |
US8012714B2 (en) | 2008-04-14 | 2011-09-06 | Innovative Targeting Solutions, Inc. | Sequence diversity generation in immunoglobulins |
WO2009143472A2 (en) | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
DK3456190T3 (da) | 2008-06-27 | 2022-02-14 | Merus Nv | Antistofproducerende transgent murint dyr |
CA3038954A1 (en) | 2008-09-30 | 2010-04-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CN102292445A (zh) | 2008-12-18 | 2011-12-21 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
EP2394159B1 (en) | 2009-02-04 | 2018-09-26 | Molecular Innovations | Assays for detecting prorenin, and antibodies used therein |
EP2401298A1 (en) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Antigen-binding constructs |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
CA2757178C (en) | 2009-04-03 | 2020-05-19 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
JP2012531208A (ja) | 2009-06-26 | 2012-12-10 | シー レーン バイオテクノロジーズ, エルエルシー | 代替軽鎖の発現 |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
LT3241435T (lt) | 2009-07-08 | 2021-10-25 | Kymab Limited | Gyvūnų modeliai ir terapinės molekulės |
WO2011008093A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
EP2464220A4 (en) | 2009-08-13 | 2014-05-07 | Crystal Bioscience Inc | Transgenic animal for the production of antibodies with minimal complementarity-determining regions |
EP2496706A4 (en) | 2009-11-05 | 2013-07-17 | Anaptysbio Inc | PROCESS FOR PREPARING IMPROVED ANTIGEN BINDING OF THE CHAIN FORMING AND OPTIONAL SOMATIC HYPERMUTATION |
CN102803488A (zh) | 2009-11-17 | 2012-11-28 | 协和发酵麒麟株式会社 | 人类人工染色体载体 |
EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
RU2603102C2 (ru) | 2009-12-10 | 2016-11-20 | Ридженерон Фармасьютикалз, Инк. | Мыши, которые производят антитела, имеющие только тяжелые цепи |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
MX350983B (es) | 2010-02-08 | 2017-09-27 | Regeneron Pharma | Raton de cadena ligera comun. |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
NZ605966A (en) | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
NO2905338T3 (ar) | 2010-06-22 | 2017-12-30 | ||
EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
JP5997154B2 (ja) | 2010-08-16 | 2016-09-28 | ノビミューン エスアー | 多重特異性多価抗体の生成方法 |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
BR112013015687A2 (pt) | 2010-12-22 | 2016-10-11 | Genentech Inc | anticorpo anti-pcsk9 ou um fragmento de anticorpo que se liga a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar um anticorpo anti-pcsk9, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito e método de tratamento de hipercolesterolemia em um sujeito |
IN2013CN07629A (ar) | 2011-02-25 | 2015-08-07 | Regeneron Pharma | |
RU2664232C2 (ru) | 2011-08-05 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной универсальной легкой цепью |
EP2758535B1 (en) | 2011-09-19 | 2016-11-09 | Kymab Limited | Antibodies, variable domains&chains tailored for human use |
EP2758534B1 (en) | 2011-09-19 | 2020-04-29 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
PL2627773T3 (pl) | 2011-10-17 | 2017-11-30 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
US20130102031A1 (en) | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
EP3527070A1 (en) | 2011-12-20 | 2019-08-21 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
SG11201404477YA (en) | 2012-02-01 | 2014-08-28 | Regeneron Pharma | HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS |
NZ714516A (en) | 2012-03-02 | 2017-06-30 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
KR20140136462A (ko) | 2012-03-06 | 2014-11-28 | 리제너론 파마슈티칼스 인코포레이티드 | 공통 경쇄 마우스 |
SG11201405164QA (en) | 2012-03-16 | 2014-10-30 | Regeneron Pharma | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
NZ728024A (en) | 2012-05-25 | 2019-05-31 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US10238093B2 (en) | 2012-06-12 | 2019-03-26 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
IL293526A (en) | 2012-12-12 | 2022-08-01 | Harvard College | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US20140331339A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Limited | Transgenic Non-Human Assay Vertebrates, Assays and Kits |
US20140331344A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Ltd. | Transgenic Animals |
ES2859373T3 (es) | 2013-10-01 | 2021-10-01 | Kymab Ltd | Modelos animales y moléculas terapéuticas |
-
2012
- 2012-03-29 US US13/434,361 patent/US9253965B2/en active Active
- 2012-11-30 WO PCT/GB2012/052960 patent/WO2013061098A2/en active Application Filing
- 2012-11-30 EP EP12795841.1A patent/EP2785845A2/en not_active Withdrawn
-
2013
- 2013-03-18 IN IN1879MUN2014 patent/IN2014MN01879A/en unknown
- 2013-03-18 CA CA2867530A patent/CA2867530A1/en not_active Abandoned
- 2013-03-18 DK DK13711119.1T patent/DK2831244T3/en active
- 2013-03-18 EP EP13711119.1A patent/EP2831244B1/en active Active
- 2013-03-18 EP EP18153171.6A patent/EP3366126B1/en active Active
- 2013-03-18 SG SG11201405058WA patent/SG11201405058WA/en unknown
- 2013-03-18 AU AU2013239501A patent/AU2013239501B2/en not_active Expired - Fee Related
- 2013-03-18 NZ NZ629202A patent/NZ629202A/en not_active IP Right Cessation
- 2013-03-18 CN CN201380027944.1A patent/CN104334732B/zh active Active
- 2013-03-18 WO PCT/GB2013/050682 patent/WO2013144566A2/en active Application Filing
- 2013-03-18 JP JP2015502439A patent/JP6336435B2/ja active Active
-
2015
- 2015-02-06 HK HK15101357.8A patent/HK1200872A1/xx unknown
-
2016
- 2016-02-08 US US15/018,670 patent/US9924705B2/en active Active
- 2016-12-19 US US15/383,196 patent/US9938357B2/en active Active
- 2016-12-19 US US15/383,202 patent/US9938358B2/en active Active
-
2018
- 2018-04-09 US US15/948,709 patent/US10774155B2/en active Active
- 2018-05-02 JP JP2018088749A patent/JP2018119012A/ja active Pending
-
2020
- 2020-07-30 JP JP2020129123A patent/JP2020176140A/ja active Pending
- 2020-09-15 US US17/020,997 patent/US20210079118A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/947,884 patent/US20230159660A1/en active Pending
- 2022-11-04 JP JP2022177513A patent/JP7475415B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01879A (ar) | ||
WO2015049517A3 (en) | Animal models and therapeutic molecules | |
HK1162119A1 (en) | Animal models and therapeutic molecules | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
NZ700823A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
EP2604110A3 (en) | Animal models and therapeutic molecules | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MY178142A (en) | Anti-phf-tau antibodies and their uses | |
EA201790664A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
EP4324480A3 (en) | Anti-transferrin receptor antibodies and methods of use | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
IN2014MN01642A (ar) | ||
EA201390847A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
MX2014004326A (es) | Anticuerpos a cd1d. | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. |